Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



How Does Johnson & Johnson Boost its Returns?

As investors, we need to understand how our companies truly make their money. A neat trick developed for just that purpose -- the DuPont Formula -- can help us do so.

So in this series we let the DuPont do the work. Let's see what the formula can tell us about Johnson & Johnson (NYSE: JNJ  ) and a few of its peers.

The DuPont Formula can give you a better grasp on exactly where your company is producing its profit, and where it might have a competitive advantage. Named after the company where it was pioneered, the formula breaks down return on equity into three components:

Return on equity = net margin x asset turnover x leverage ratio

What makes each of these components important?

  • High net margins show that a company can get customers to pay more for its products. Luxury-goods companies provide a great example here.
  • High asset turnover indicates that a company needs to invest less of its capital, since it uses its assets more efficiently to generate sales. Service industries, for instance, often lack big capital investments.
  • Finally, the leverage ratio shows how much the company is relying on liabilities to create its profits.

Generally, the higher these numbers, the better. That said, too much debt can sink a company, so beware of companies with very high leverage ratios.

So what does DuPont say about these four companies?


Return on Equity

Net Margin

Asset Turnover

Leverage Ratio

Johnson & Johnson 19.2% 17.7% 0.61 1.77
Abbott Laboratories (NYSE: ABT  ) 19.7% 11.8% 0.66 2.53
Eli Lilly (NYSE: LLY  ) 33.9% 19.1% 0.78 2.29

Source: S&P Capital IQ.

Johnson & Johnson's returns on equity fall in with Abbott Labs, while Eli Lilly offers a very high ROE. Johnson & Johnson's leverage ratio and asset turnover are at the bottom of the range seen among the three companies. All three net margins are quite high.

Johnson & Johnson is a nice play for conservative investors as an all-purpose health stock producing health-related consumer goods, medical devices, and pharmaceuticals.

Johnson & Johnson has struggled over the past couple of years due to recalls that cost the company $900 million in sales and a weak economy preventing patients from having elective medical procedures. The recalls have caused customers to turn to competitors like Procter & Gamble and Kimberly-Clark. While it has struggled to grow much over the past couple of years due to recalls, that may give investors an opportunity to buy some shares at a low price. It is likely that these recalls will result in continued slow growth as the company works to win those customers back.

Industry peers in the medical device market like Medtronic (NYSE: MDT  ) and Intuitive Surgical (Nasdaq: ISRG  ) have also suffered from weak sales in the face of the fragile economy.

Despite the slow growth in recent years, Johnson & Johnson has a strong track record of bouncing back from tough times (as evidenced by its recovery from the Tylenol recall in 1982), and so the company's current struggles provide a nice opportunity for investors to buy at low prices. Also, its 3.6% dividend yield makes the company a strong pick for those seeking dividend income.

Using the DuPont formula can often give you some insight into how a company is competing against peers and what type of strategy it's using to juice return on equity. To find more successful investments, dig deeper than the earnings headlines.

If you'd like to add these companies to your watchlist, or set up a new one, just click below:

Jim Royal, Ph.D., owns shares of Johnson & Johnson. The Motley Fool owns shares of Abbott Laboratories, Medtronic, and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Abbott Laboratories, Procter & Gamble, Intuitive Surgical, and Johnson & Johnson, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1739677, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:30:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:01 PM
JNJ $113.44 Down -1.43 -1.24%
Johnson and Johnso… CAPS Rating: ****
ABT $40.50 Down -0.24 -0.59%
Abbott Laboratorie… CAPS Rating: *****
ISRG $678.02 Down -3.80 -0.56%
Intuitive Surgical CAPS Rating: ****
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
MDT $83.91 Down -0.11 -0.13%
Medtronic CAPS Rating: *****